Southern Research awarded NCI contract

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

SOUTHERN RESEARCH was awarded a five-year Indefinite-Delivery Indefinite-Quantity contract from NCI. This is to investigate the pharmacokinetic properties of antitumor and other therapeutic agents of interest to the Division of Cancer Treatment and Diagnosis (DCTD) under NCI contract HHSN261201600021I. RFP number N02CM67000-11 was issued under full and open competition, which resulted in five IDIQ awards....

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login